text update

Author: kate-fie

4_cure_zika.ipynb

@@ -7,7 +7,7 @@
    "source": [
     "## Part 4: Designing improved inhibitors for the Zika virus NS2B–NS3 protease (PDB: 7I9O) 🦟❌\n",
     "\n",
-    "Following Part 3 where we introduced the NS2B-NS3 protease target and the resolved inhibitor (PDB: 7I9O), in this notebook you will make your own decisions acting as an early-stage antiviral drug designer. The following information was already defined in Part 2 but included to remind you again.\n",
+    "Following Part 3 where we introduced the NS2B-NS3 protease target and the resolved inhibitor (PDB: 7I9O), in this notebook you will make your own decisions acting as an early-stage antiviral drug designer. The following information was already defined in Part 3 but included to remind you again.\n",
     "\n",
     "Our biological target is the **Zika virus NS2B–NS3 protease**, a serine protease formed by the NS3 catalytic domain together with its NS2B cofactor. This protease is essential for ZIKV replication because it cleaves the viral polyprotein into the individual structural and non-structural proteins the virus needs to assemble and replicate, which makes it a high-value antiviral target. ([Nature][1])\n",
     "We will use the experimentally solved crystal structure **7I9O**, which captures the ZIKV NS2B–NS3 protease bound to a small-molecule inhibitor. ([rcsb.org][2])\n",